FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1

DOI: 10.1634/theoncologist.2018-0221

Keywords: GEJ adenocarcinoma, Accelerated approval, PD‐L1

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text